TSW
ANIP icon

Thompson Siegel & Walmsley’s ANI Pharmaceuticals ANIP Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.69M Buy
113,003
+12,944
+13% +$1.01M 0.15% 148
2025
Q4 		$7.9M Buy
100,059
+8,626
+9% +$747K 0.13% 158
2025
Q3 		$8.38M Sell
91,433
-152,987
-63% -$12.5M 0.14% 152
2025
Q2 		$15.9M Buy
244,420
+7,393
+3% +$481K 0.27% 95
2025
Q1 		$15.9M Sell
237,027
-46,833
-16% -$2.8M 0.27% 94
2024
Q4 		$15.7M Buy
283,860
+53,701
+23% +$3.08M 0.24% 101
2024
Q3 		$13.7M Buy
230,159
+34,416
+18% +$2.1M 0.2% 110
2024
Q2 		$12.5M Buy
195,743
+2,986
+2% +$194K 0.2% 111
2024
Q1 		$13.3M Sell
192,757
-20,154
-9% -$1.22M 0.2% 109
2023
Q4 		$11.7M Sell
212,911
-15,796
-7% -$870K 0.19% 116
2023
Q3 		$13.3M Sell
228,707
-133,584
-37% -$7.71M 0.22% 101
2023
Q2 		$19.5M Sell
362,291
-31,498
-8% -$1.4M 0.31% 87
2023
Q1 		$15.6M Sell
393,789
-21,491
-5% -$906K 0.25% 96
2022
Q4 		$16.7M Sell
415,280
-682
-0.2% -$25.6K 0.27% 97
2022
Q3 		$13.4M Sell
415,962
-19,911
-5% -$682K 0.23% 109
2022
Q2 		$12.9M Buy
435,873
+11,786
+3% +$340K 0.21% 114
2022
Q1 		$11.9M Buy
424,087
+144,533
+52% +$5.39M 0.17% 134
2021
Q4 		$12.9M Sell
279,554
-170,950
-38% -$7.35M 0.18% 136
2021
Q3 		$14.8M Buy
450,504
+70,030
+18% +$2.18M 0.21% 115
2021
Q2 		$13.3M Buy
380,474
+51,935
+16% +$1.77M 0.18% 120
2021
Q1 		$11.9M Sell
328,539
-4,268
-1% -$134K 0.17% 127
2020
Q4 		$9.66M Sell
332,807
-4,231
-1% -$121K 0.15% 133
2020
Q3 		$9.51M Buy
337,038
+38,104
+13% +$1.13M 0.18% 119
2020
Q2 		$9.67M Buy
298,934
+294,992
+7,483% +$10.6M 0.19% 114
2020
Q1 		$161K Buy
+3,942
New +$210K ﹤0.01% 329

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thompson Siegel & Walmsley's ANIP Position: Q1 2026 in Review

Thompson Siegel & Walmsley increased its ANI Pharmaceuticals (ANIP) stake by 13% in Q1 2026, buying an estimated $1.01M and bringing the position to 113,003 shares worth $8.69M. The position accounts for 0.15% of the portfolio, ranked #148.

Thompson Siegel & Walmsley first reported a position in ANIP in Q1 2020 and has held it in 25 quarters since. The position peaked at $19.5M in Q2 2023. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Thompson Siegel & Walmsley held 113,003 shares of ANI Pharmaceuticals worth $8.69M as of Q1 2026.
  • Thompson Siegel & Walmsley bought 12,944 ANI Pharmaceuticals shares in Q1 2026, an estimated $1.01M.
  • ANI Pharmaceuticals made up 0.15% of Thompson Siegel & Walmsley's portfolio in Q1 2026, its #148 holding.
  • Thompson Siegel & Walmsley first reported a position in ANI Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Thompson Siegel & Walmsley's ANI Pharmaceuticals position peaked at $19.5M in Q2 2023.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2026, filed 11 May 2026.